Alnylam Assist: Screening for Familial Amyloidotic Polyneuropathy (FAP) in TTR Amyloidosis

Similar documents
Education Brochure. Hereditary ATTR amyloidosis A closer look at an inherited condition

reversing familial amyloid polyneuropathy naturally the raw vegan plant based detoxification regeneration workbook for healing patients volume 2

Hereditary ATTR amyloidosis Talking to your healthcare professional about a hereditary condition

Corporate Medical Policy

Testing for Fabry Disease. What You Need to Know

Family Tree. Family Health Tree Map your family s history of hereditary ATTR amyloidosis

Russell-Silver syndrome (RSS)

YES. If yes, indicate what types of tumors/polyps and age of onset:

Hypertrophy of liver Neonatal hypoglycemia Omphalocele Large for gestational age Other:

Subject: Patisiran (Onpattro )

Genetic testing for hereditary cancer. An overview for healthcare providers

IRB Approval From: 3/8/2010 To: 10/28/2010

Xiaoping (Amy) Zhang, Varun Goel, Husain Attarwala, and Gabriel Robbie. Alnylam Pharmaceuticals, Cambridge, USA

Hereditary ATTR (hattr) Amyloidosis: Polyneuropathy An Overview. Identifying the link can lead to a crucial diagnosis

Varun Goel 1, Nathalie H Gosselin 2, Claudia Jomphe 2, Husain Attarwala 1, Xiaoping (Amy) Zhang 1, JF Marier 2, Gabriel Robbie 1

Conference Call to Discuss FDA Approval of ONPATTRO (patisiran)

Summary of plenary sessions on October 31, 2015

Progress in the Treatment of Cardiac Amyloidosis

Safety and Efficacy of Inotersen in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (NEURO-TTR) Annabel K.

2016 icd 10 code for idiopathic peripheral neuropathy

Providence Medford Medical Center Pathology Department

EMORY NEUROMUSCULAR LABORATORY

About this consent form. Why is this research study being done? Partners HealthCare System Research Consent Form

Y. Harati, M.D., F.A.C.P. Department of Neurology Professor Neuromuscular Disease Director Neuromuscular Pathology Laboratory

THE IBECA SHOW PRESENTS HOW TO WIN! July Park Place Hotel, Traverse City, MI

Booth Size MIIAB Company Members Non-Members Power in Partner Sponsor 8 x 10 $1250 $1500 *Free Booth

Neuropathy. Nerves before and after TTR. Márcia Waddington Cruz. CEPARM HUCFF-UFRJ.

Hereditary ATTR (hattr) Amyloidosis: Cardiomyopathy An Overview. Identifying the link can lead to a crucial diagnosis

Epidermal Nerve Fiber Density

Boo & Brew Ball. October 29 th, pm 12am Venue W. Central

University of Utah. Cutaneous Nerve Evaluation. Please read through all information BEFORE scheduling patient s biopsy

Washington County Public Health Achievement Awards

: A Study Examining the Prevalence of Transthyretin Mutations in Subjects Suspected of Having Cardiac Amyloidosis


SAFETY AND EFFICACY OF INOTERSEN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS POLYNEUROPATHY (hattr-pn) Teresa Coelho, MD

Conference Sponsor Information: Letters and Forms

OFFICERS LETTER OF REQUEST:

Mental Health Association of San Francisco Sponsorship and Exhibitor Packet. 18th International Conference on Hoarding and Cluttering

10/7/ Immediate Action, Quest Diagnostics Nichols Institute, Valencia

AL amyloidosis and autonomic neuropathy

extremities, bilateral icd 10

SeniorMed Education Forum 2008 Piecing Together Today s Senior Healthcare Puzzle. May 1, Tampa Marriott Westshore

THE PETER PAN CHILDREN S FUND PETER PAN HOSPITAL GIFT APPLICATION

2. Receive the Guidelines for the Allergist letter which is to be given to the prescribing allergist physician.

A Novel Variant Mutation of Transthyretin Ile73Val-Related Amyloidotic Polyneuropathy in Taiwanese

FIRST NAME MI LAST NAME BIRTH DATE (MM/DD/YYYY) GENDER. Name of person previously tested and relationship:

Familial Amyloidosis. What Does it Mean for Your Family? Teresa Kruisselbrink, MS Certified Genetic Counselor Mayo Clinic, Rochester MN

Society of Plastic Surgical Skin Care Specialists 24 th Annual Meeting - Exhibitor Prospectus Exhibit Dates: April 26-27, 2018

Alzheimer s disease Treatment options

Michigan Psychological Association. Ethics: What to Know Before You Need to Know It

March Monthly Update, Quest Diagnostics Nichols Institute, Valencia

The landscape of ATTR amyloidosis treatment

Some of the benefits to your entity as a member of the Local Government Testing Consortium (LGTC), are as follows:

SEPTEMBER 15 21, 2014 SPONSORSHIP PACKET BALANCE AWARENESS WEEK VESTIBULAR.ORG/BAW

PATIENT AUTHORIZATION AND NOTICE OF RELEASE OF INFORMATION (PAN)

Kristi Mellion. Dear Community Member

Michigan Psychological Association (MPA) along with Michigan Association of Professional Psychologists (MAPP)

Prevent. Educate. Empower.

Phase 2 Open-Label Extension Study of Patisiran An RNAi Therapeutic for the Treatment of Familial Amyloidotic Polyneuropathy

Cleveland Clinic Laboratories. Trust in us for everything you need in a reference lab.


Lynch Syndrome. patient guide. genetic testing for hereditary colorectal and uterine cancer

LETTER OF REQUEST: OFFICERS

Colorectal Cancer Screening

Denver, August 29, 2010

Test Definition: FNMR2 NMR LipoProfile w/ir Markers

NYS Parent Teacher Association Strategic Alliance Working collaboratively to support New York s children, families and educators

Home Delivery Pharmacy Program. mycigna.com k 1/07

National Association of Royalty Owners National Convention October 6-8, 2016 Hilton DFW Lakes Executive Conference Center

Miles for Melanoma San Diego November 12, Local Sponsorship Opportunities

Peripheral Nerve Amyloidosis in Sural Nerve Biopsies. A Clinicopathologic Analysis of 13 Cases

SPONSORSHIP & EXHIBITION 2019

Sponsorship Opportunities

Clinical Profile FOR. Indication. Important Safety Information

What to do if you are unhappy with the service you have received from the Tenancy Deposit Scheme

IU Health Pathology Laboratory. DOS Updates

Neuren s trofinetide successful in proof of concept Phase 2 clinical trial in Fragile X syndrome

Minority Health Conference 2010

CCC Bike Tour Fundraising Materials Guide

Exhibitor s Registration and Information Packet

FFMIA Corporate Membership Program FAQ s

Neuro-IFRAH Certification Course in the Treatment and Management of Adults with Hemiplegia from a Stroke or Brain Injury


A Guide for Patients and Caregivers

patient guide Hereditary Cancer genetic testing panels Because knowing your risk can mean early detection and prevention

EXECUTIVE (EIGHT: ASC PROGRAM ASC RECEPTION VIP DINNER NETWORKING LUNCHEON KEYNOTE SPEAKER NETWORKING RECEPTION LANYARDS NETWORKING BREAKS [2])

MAGNETIC RESONANCE IMAGING (MRI) PATIENT EDUCATION

Indianapolis, IN Saturday, June 25, 2011

Integrated Healthcare Association 2016 IHA Stakeholders Meeting

OBSERVATION. Akira Yoshioka, MD; Yoko Yamaya, MD; Shinji Saiki, MD; Genjiro Hirose, MD; Kohei Shimazaki, MD; Masaaki Nakamura, MD; Yukio Ando, MD

Brown-Lupton Health Service Texas Christian University Campus P.O. Box Fort Worth, TX Dear Student,

2019 NATIONAL HOSPICE SPONSORSHIP AND AUCTION OPPORTUNITIES TUESDAY, APRIL 16, :30PM 11:00PM MARRIOTT WARDMAN PARK - WASHINGTON, DC

Hereditary Gynecologic Cancer

Safety Regulations and Procedures Occupational Health Bloodborne Pathogens Exposure Control Plan S80.10, updated, May Contains information for:

Adult Metabolic Diseases Clinic 4 th Floor 2775 Laurel Street Vancouver, BC V5Z 1M9 Tel: Fax:

BRCA1 and BRCA2. patient guide. genetic testing for hereditary breast and ovarian cancer (hboc)

Fort McMurray Community Cancer Centre Patient Guide for Cancer Care

Massachusetts General Hospital Handbook of Pain Management Lippinott 2002; 350:382 In most cases of neck and back pain the anatomic and physiologic

SPONSORSHIP AND AD OPPORTUNITIES

2013 Certificate in Spinal Manual Therapy

Transcription:

FREE Screening Program* Alnylam Assist: Screening for Familial Amyloidotic Polyneuropathy (FAP) in TTR Amyloidosis Alnylam Pharmaceuticals, Inc. is committed to advancing the diagnosis and treatment of FAP. As part of our commitment, Alnylam is now sponsoring free third party screening for patients who may carry a genetic mutation known to be associated with FAP. *Available only in the US.

Why screen your patients for Familial Amyloidotic Polyneuropathy (FAP) FAP is an inherited genetic disorder caused by deposition of liver-derived TTR amyloid in various tissues and organs. This progressive condition remains significantly underdiagnosed and has limited treatment options. FREE Screening Program* Diagnosing FAP can be a challenge. Patients often exhibit symptoms commonly associated with idiopathic polyneuropathies. To promote accurate diagnosis and appropriate treatment, Alnylam Assist offers free third party screening for family members of patients diagnosed with FAP as well as for patients experiencing clinical signs and symptoms of this condition. FAP symptoms experienced at disease onset Sensory symptoms Motor symptom Autonomic symptoms Loss of touch/pain 82% Tingling/ pins and needles 80% Weakness 67% Constipation/diarrhea 55% Sexual dysfunction 53% Consider screening for any patient with a family history of FAP. Source: Suanprasert N, et al. J Neurol Sci 2014. *Available only in the US.

Alnylam Assist: Simple, Complimentary Screening Complete the included LabCorp account setup form Form for FAP testing is enclosed Complete LabCorp requisition form To be sent by LabCorp after account setup is completed. To ensure your practice or patient will not be billed, please use the requisition form sent by LabCorp only for the FAP Screening Program. Submit the requisition form to LabCorp Phone: 1.919.474.4326 Fax: 1.919.474.4382 E-mail: TTRSupport@LabCorp.com Attention: Jill Hulford Take a 4 ml whole blood sample Use a standard 4.0 ml lavender-top (EDTA) tube Send the sample to LabCorp Shipping and specimen handling instructions are provided by LabCorp after account setup Receive your patient s results in 2-3 weeks Results will be faxed to your clinic For assistance with the LabCorp account setup form, contact LabCorp by calling 1.919.474.4326. For more information about FAP, contact Alnylam by calling 1.866.330.0326. Alnylam will not receive any personally identifiable patient information through this screening program. s Screening information sheet to distribute to patients you believe may benefit from this free FAP screening program. s Account setup form to complete and send to LabCorp.

Tremendous advances are being made in Familial Amyloidotic Polyneuropathy (FAP) research. This free screening program offered by Alnylam gives patients and their physicians access to laboratory testing for genetic mutations known to be associated with this serious, life-threatening disease. This screening is expected to help enable earlier diagnosis and enhance a patient s knowledge of the disorder and how it might affect them and their family members. It will also allow them to initiate discussions with their healthcare provider about their care, and potentially enable them to consider participating in ongoing clinical trials. Natacha T. Pires, MBBS, Director of Medical and Public Affairs, The Neuropathy Association Alnylam is a biopharmaceutical company developing a new class of innovative medicines. We have a core focus on therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers. Learn more about Alnylam s clinical trial of a potential new treatment for FAP. Visit www.clinicaltrials.gov, www.apollotrial.com or call 1.866.330.0326 for more information. 2014 Alnylam Pharmaceuticals, Inc. 300 Third Street Cambridge, MA 02142 USA Rev_1_10.10.2014

Alnylam Assist: Free Screening for Familial Amyloidotic Polyneuropathy (FAP) * Your doctor believes you should be screened for familial amyloidotic polyneuropathy (FAP), an inherited genetic disease. Alnylam offers you this screening through an independent laboratory free of charge. Early diagnosis can assist patients with FAP in getting the help and support they need. How To Get Screened 1. Provide a blood sample Screening for FAP takes a small amount of blood. 2. Get your results from your doctor FAP screening results usually arrive in 2-3 weeks. If your results are positive When your results arrive, your doctor will tell you if you have a genetic mutation known to be associated with FAP. If you do, you are encouraged to discuss health care options with your doctor. If you need treatment, options may include drug therapy or a clinical trial. To learn more about clinical trials for FAP, visit www.clinicaltrials.gov or www.apollotrial.com. * Available only in the US. Alnylam will not receive any personally identifiable patient information through this screening program.

sponsored by